A Phase 1 interventional study of LAM-002A and Rituximab in Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic, sponsored by OrphAI Therapeutics. Completed at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-22.
Sponsored by OrphAI Therapeutics · Phase 1, Interventional, and Treatment
How we know · 11 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 178 studies testing rituximab in Lymphoma, Non-Hodgkin — 5 open to participants now, 11 under way, 2 of them phase 3. Rituximab · Lymphoma, Non-Hodgkin.
Among the 178 studies testing rituximab in Lymphoma, Non-Hodgkin, this one is the 55th largest by enrollment of the 171 interventional ones that give a count, is one of 6 that started in 2015, is one of 26 in phase 1, and was the 154th registered.
2,289 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →5 of the 178 studies testing rituximab in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:
Paolo Caimi, MD · Sites in United States
Ages 18+
Reid Merryman, MD · Sites in United States
Ages 18+
University of Cologne · Sites in Germany
Ages 18–99
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
M.D. Anderson Cancer Center · Sites in United States
Ages 15–80
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 241 Lymphoma, Non-Hodgkin studies recruiting now, 141 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
178 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 43 · Phase 2 112 · Phase 3 30 · Phase 4 5
First in 1995; this study’s year is marked. 6 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 62 is above the median of 40 across 1,884 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 38 across the 171 interventional studies. Of the 152 that completed or were terminated, 80 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 178 have an industry lead sponsor. The 10 most frequent:
OrphAI Therapeutics is the lead sponsor of 4 studies on the registry; none are open to participants now.
OrphAI Therapeutics has 1 study filed under Lymphoma, Non-Hodgkin — fewer than ten, so there is no comparison to draw.
4 of the studies testing rituximab in Lymphoma, Non-Hodgkin that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05578976Phase 3GenmabA Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | 2027-06 |
| NCT05583071University of CologneMethotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL | 2027-02 |
| NCT01829958Memorial Sloan Kettering Cancer CenterComprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy | 2027-04 |
| NCT02727803M.D. Anderson Cancer CenterPersonalized NK Cell Therapy in CBT | 2027-05-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 178 studies testing rituximab in Lymphoma, Non-Hodgkin, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1 dose-exploration study of LAM-002A administered by mouth in patients with relapsed or refractory B-cell NHL. Safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD),and preliminary anti-tumor activity will be evaluated.
LAM-002A is supplied as 25-mg or 50-mg capsules and will be administered two times daily or three times daily by mouth in repeated 28-day cycles. Patients will be advised to take the doses at the same time each day.
A 3 + 3 design will be utilized to define a maximum tolerated dose (MTD). The MTD is defined as the highest dose at which no more than 1 of 6 patients (i.e., \< 33%) experiences a dose-limiting toxicity (DLT) in the dose cohort.
Once the dose and schedule are established, additional patients will be treated to better characterize the safety, tolerability,PK, PD, and anti-tumor activity of LAM-002A when administered alone or in combination with rituximab or atezolizumab.
2,289 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.
This study's enrollment of 62 is above the median of 40 across 1,884 interventional studies indexed under Lymphoma, Non-Hodgkin.
Browse Lymphoma, Non-Hodgkin studies →OrphAI Therapeutics is the lead sponsor of 4 studies on the registry; none are open to participants now.
Compared within Lymphoma, Non-Hodgkin, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This is a shortened list and additional criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients will take LAM-002A two times daily by mouth every day until cancer progression or intolerability.
Drug: LAM-002A
All patients will receive LAM-002A at escalating dose levels two times daily by mouth for 3 days on therapy followed by 4 days off therapy every week until cancer progression or intolerability.
Drug: LAM-002A
All patients will receive LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and rituximab 375 mg/m2 by vein every week for 4 weeks and then every 8 weeks for 4 times (total of 8 infusions)
Drug: Rituximab
All patients will receive LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and atezolizumab 1200 mg by vein every 3 weeks until cancer progression or intolerability
Drug: Atezolizumab
25 mg capsules or 50 mg capsules
Also known as: apilimod dimesylate
375 mg/m2 by vein
Also known as: rituxan
1200 mg by vein
Also known as: Tecentriq
Determination of the Maximum Tolerated Dose (MTD) of Continuous Oral LAM-002A
MTD was determined by testing increasing doses up to 125 mg twice a day or 75 mg three times a day orally on dose escalation cohorts with 3 to 6 participants each. In the dose escalation, the cohort sizes of 3 to 6 subjects allow evaluation of regimen safety using a standard definition of MTD (ie, the highest starting dose associated with DLT in \<33% of subjects during the first cycle of therapy) when administered continuously (daily administration) and then when administered intermittently (repeated courses of 3 days on and 4 days off).
Time frame: 28 days
Peak Plasma Concentration (Cmax) of LAM-002A
Evaluation of the peak plasma concentration (Cmax) of LAM-002A and its metabolites in plasma on Day 1 and Day 8.
Time frame: 8 days
Area Under the Plasma Concentration Versus Time Curve (AUC) of LAM-002A
Evaluation of the Area under the concentration-time curve from time-zero to the time of the last quantifiable concentration (AUClast) of LAM-002ALAM-002A and its metabolites in plasma on Day 1 and Day 8.
Time frame: 8 days
Objective Response Rate
Anti-tumor response as assessed by investigator according to modified Hallek or Lugano Response Criteria by Disease Type and Cohort
Time frame: 1 cycle (28 days) up to a maximum of 24 cycles
This study was conducted at 12 study centers in the United States, 11 of which enrolled subjects to the trial.
| Milestone | LAM-002A Continuous Monotherapy - 50 mg BID | LAM-002A Continuous Monotherapy - 100 mg BID | LAM-002A Continuous Monotherapy - 150 mg BID | LAM-002A Continuous Monotherapy - 75 mg TID | LAM-002A Intermittent Monotherapy - 150 mg BID | LAM-002A Continuous Monotherapy - 125 mg | LAM-002A + Rituximab | LAM-002A + Atezolizumab |
|---|---|---|---|---|---|---|---|---|
| Started | 3 | 8 | 5 | 4 | 3 | 20 | 12 | 7 |
| Completed | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 0 |
| Not completed | 3 | 8 | 5 | 4 | 3 | 19 | 9 | 7 |
| Withdrew: Disease progression | 3 | 7 | 0 | 2 | 2 | 12 | 5 | 5 |
| Withdrew: Adverse event | 0 | 1 | 4 | 1 | 0 | 6 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 |
| Withdrew: Progressive leukocytosis | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Substantial noncompliance | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
MTD was determined by testing increasing doses up to 125 mg twice a day or 75 mg three times a day orally on dose escalation cohorts with 3 to 6 participants each. In the dose escalation, the cohort sizes of 3 to 6 subjects allow evaluation of regimen safety using a standard definition of MTD (ie, the highest starting dose associated with DLT in \<33% of subjects during the first cycle of therapy) when administered continuously (daily administration) and then when administered intermittently (repeated courses of 3 days on and 4 days off).
| mg BID | All Participants |
|---|---|
| Determination of the Maximum Tolerated Dose (MTD) of Continuous Oral LAM-002A | 125 |
Evaluation of the peak plasma concentration (Cmax) of LAM-002A and its metabolites in plasma on Day 1 and Day 8.
| ng/mL | LAM-002A Continuous Monotherapy - 50 mg BID | LAM-002A Continuous Monotherapy - 75 mg TID | LAM-002A Continuous Monotherapy - 100 mg BID | LAM-002A Continuous Monotherapy - 125 mg BID | LAM-002A Continuous Monotherapy - 150 mg BID | LAM-002A Intermittent Monotherapy - 150 mg |
|---|---|---|---|---|---|---|
| Apilimod - Day 1 | 117 ± 69.6 | 158 ± 61.6 | 263 ± 168 | 207 ± 82.4 | 243 ± 76.1 | 280 ± 135 |
| Apilimod - Day 8 | 140 ± 95.1 | 339 ± 215 | 331 ± 273 | 331 ± 287 | 369 ± 90.5 | 108 |
| STA-5908 - Day 1 | 112 ± 85.0 | 114 ± 71.6 | 215 ± 88.6 | 144 ± 92.5 | 196 ± 142 | 207 ± 135 |
| STA-5908 - Day 8 | 103 ± 43.7 | 239 ± 195 | 278 ± 137 | 234 ± 173 | 240 ± 99.7 | 113 |
| STA-5944 - Day 1 | 209 ± 145 | 243 ± 124 | 346 ± 131 | 281 ± 125 | 369 ± 306 | 466 ± 247 |
| STA-5944 - Day 8 | 188 ± 101 | 436 ± 334 | 439 ± 215 | 383 ± 225 | 391 ± 9.90 | 260 |
| STA-6048 - Day 1 | 63.2 ± 40.2 | 59.9 ± 54.0 | 136 ± 64.2 | 90.0 ± 58.6 | 131 ± 134 | 145 ± 66.0 |
| STA-6048 - Day 8 | 60.6 ± 32.0 | 154 ± 113 | 161 ± 43.0 | 122 ± 81.7 | 116 ± 87.4 | 140 |
Evaluation of the Area under the concentration-time curve from time-zero to the time of the last quantifiable concentration (AUClast) of LAM-002ALAM-002A and its metabolites in plasma on Day 1 and Day 8.
| h*ng/mL | LAM-002A Continuous Monotherapy - 50 mg BID | LAM-002A Continuous Monotherapy - 75 mg TID | LAM-002A Continuous Monotherapy - 100 mg BID | LAM-002A Continuous Monotherapy - 125 mg BID | LAM-002A Continuous Monotherapy - 150 mg BID | LAM-002A Intermittent Monotherapy - 150 mg BID |
|---|---|---|---|---|---|---|
| Apilimod - Day 1 | 238 ± 88.1 | 583 ± 290 | 515 ± 221 | 562 ± 234 | 700 ± 290 | 777 ± 437 |
| Apilimod - Day 8 | 374 ± 119 | 1040 ± 483 | 1130 ± 930 | 1290 ± 1040 | 1060 ± 85.7 | 563 |
| STA-5944 - Day 1 | 542 ± 214 | 1020 ± 659 | 1120 ± 550 | 1180 ± 587 | 1590 ± 1420 | 1700 ± 843 |
| STA-5944 - Day 8 | 653 ± 365 | 2070 ± 1430 | 1810 ± 1240 | 1860 ± 1160 | 1320 ± 211 | 1350 |
| STA-5908 - Day 1 | 312 ± 156 | 526 ± 291 | 762 ± 371 | 625 ± 419 | 936 ± 734 | 968 ± 547 |
| STA-5908 - Day 8 | 433 ± 195 | 1140 ± 818 | 1360 ± 796 | 1270 ± 875 | 1040 ± 572 | 690 |
| STA-6048 - Day 1 | 238 ± 91.2 | 280 ± 216 | 622 ± 372 | 443 ± 325 | 785 ± 923 | 869 ± 415 |
| STA-6048 - Day 8 | 308 ± 164 | 1040 ± 780 | 959 ± 343 | 746 ± 509 | 556 ± 397 | 760 |
Anti-tumor response as assessed by investigator according to modified Hallek or Lugano Response Criteria by Disease Type and Cohort
| Participants | LAM-002A Continuous Monotherapy - 50 mg BID | LAM-002A Continuous Monotherapy - 100 mg BID | LAM-002A Continuous Monotherapy - 150 mg BID | LAM-002A Continuous Monotherapy - 75 mg TID | LAM-002A Intermittent Monotherapy - 150 mg BID | LAM-002A Continuous Monotherapy - 125 mg | LAM-002A + Rituximab | LAM-002A + Atezolizumab |
|---|---|---|---|---|---|---|---|---|
| DLBCL (diffuse large B-cell lymphoma) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| FL (follicular lymphoma) | 0 | 0 | 0 | 0 | 0 | 2 | 5 | 2 |
| MZL (marginal zone lymphoma) | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| MCL (mantle cell lymphoma) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CLL/SLL (chronic lymphocytic leukemia/ small lymphocytic lymphoma) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over Adverse Events will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. AEs, including SAEs, were captured from Cycle 1 Day 1 through 30 days after the last dose of study treatment, an average of 4.5 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LAM-002A Continuous Monotherapy - 50 mg BID | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| LAM-002A Continuous Monotherapy - 100 mg BID | 1/8 (12.5%) | 3/8 (37.5%) | 8/8 (100%) |
| LAM-002A Continuous Monotherapy - 150 mg BID | 1/5 (20%) | 1/5 (20%) | 5/5 (100%) |
| LAM-002A Continuous Monotherapy - 75 mg TID | 0/4 (0%) | 2/4 (50%) | 4/4 (100%) |
| LAM-002A Intermittent Monotherapy - 150 mg BID | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| LAM-002A Continuous Monotherapy - 125 mg BID | 3/20 (15%) | 9/20 (45%) | 20/20 (100%) |
| LAM-002A + Rituximab | 0/12 (0%) | 5/12 (41.7%) | 12/12 (100%) |
| LAM-002A + Atezolizumab | 3/7 (42.9%) | 6/7 (85.7%) | 7/7 (100%) |
| Event | LAM-002A Continuous Monotherapy - 50 mg BID | LAM-002A Continuous Monotherapy - 100 mg BID | LAM-002A Continuous Monotherapy - 150 mg BID | LAM-002A Continuous Monotherapy - 75 mg TID | LAM-002A Intermittent Monotherapy - 150 mg BID | LAM-002A Continuous Monotherapy - 125 mg BID | LAM-002A + Rituximab | LAM-002A + Atezolizumab |
|---|---|---|---|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 0/3 | 1/8 | 0/5 | 1/4 | 0/3 | 0/20 | 0/12 | 1/7 |
| Hodgkin's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 0/8 | 0/5 | 1/4 | 0/3 | 0/20 | 0/12 | 0/7 |
| SyncopeNervous system disorders | 0/3 | 0/8 | 0/5 | 1/4 | 0/3 | 0/20 | 0/12 | 0/7 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/3 | 0/8 | 0/5 | 1/4 | 0/3 | 0/20 | 0/12 | 0/7 |
| HypotensionVascular disorders | 0/3 | 0/8 | 0/5 | 1/4 | 0/3 | 0/20 | 0/12 | 0/7 |
| Lung infectionRespiratory, thoracic and mediastinal disorders | 0/3 | 0/8 | 1/5 | 0/4 | 0/3 | 0/20 | 0/12 | 0/7 |
| Tumour lysis syndromeMetabolism and nutrition disorders | 0/3 | 0/8 | 0/5 | 0/4 | 0/3 | 0/20 | 2/12 | 0/7 |
| ColitisGastrointestinal disorders | 0/3 | 0/8 | 0/5 | 0/4 | 0/3 | 0/20 | 0/12 | 1/7 |
| NauseaGastrointestinal disorders | 0/3 | 0/8 | 0/5 | 0/4 | 0/3 | 0/20 | 0/12 | 1/7 |
| Disease progressionGeneral disorders | 0/3 | 1/8 | 0/5 | 0/4 | 0/3 | 1/20 | 0/12 | 1/7 |
| Event | LAM-002A Continuous Monotherapy - 50 mg BID | LAM-002A Continuous Monotherapy - 100 mg BID | LAM-002A Continuous Monotherapy - 150 mg BID | LAM-002A Continuous Monotherapy - 75 mg TID | LAM-002A Intermittent Monotherapy - 150 mg BID | LAM-002A Continuous Monotherapy - 125 mg BID | LAM-002A + Rituximab | LAM-002A + Atezolizumab |
|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/3 | 3/8 | 3/5 | 3/4 | 0/3 | 9/20 | 6/12 | 6/7 |
| VomitingGastrointestinal disorders | 0/3 | 1/8 | 3/5 | 3/4 | 0/3 | 4/20 | 3/12 | 4/7 |
| ConstipationGastrointestinal disorders | 0/3 | 2/8 | 0/5 | 2/4 | 1/3 | 3/20 | 1/12 | 5/7 |
| DiarrhoeaGastrointestinal disorders | 1/3 | 0/8 | 2/5 | 2/4 | 2/3 | 6/20 | 6/12 | 1/7 |
| InsomniaPsychiatric disorders | 0/3 | 1/8 | 2/5 | 1/4 | 2/3 | 1/20 | 0/12 | 2/7 |
| Electrocardiogram QT prolongedInvestigations | 0/3 | 0/8 | 3/5 | 1/4 | 0/3 | 0/20 | 0/12 | 0/7 |
| FatigueGeneral disorders | 0/3 | 4/8 | 2/5 | 2/4 | 1/3 | 10/20 | 7/12 | 1/7 |
| Oedema peripheralGeneral disorders | 1/3 | 1/8 | 0/5 | 2/4 | 0/3 | 3/20 | 2/12 | 1/7 |
| Hemoglobin decreasedInvestigations | 0/3 | 3/8 | 0/5 | 2/4 | 0/3 | 5/20 | 0/12 | 1/7 |
| Blood creatinine increasedInvestigations | 0/3 | 0/8 | 1/5 | 2/4 | 0/3 | 2/20 | 1/12 | 1/7 |
Full analysis set=All subjects who received ≥1 dose of study drug.
| Age, Customized(Participants) | LAM-002A Continuous Monotherapy - 50 mg BID | LAM-002A Continuous Monotherapy - 100 mg BID | LAM-002A Continuous Monotherapy - 150 mg BID | LAM-002A Continuous Monotherapy - 75 mg TID | LAM-002A Intermittent Monotherapy - 150 mg BID | LAM-002A Continuous Monotherapy - 125 mg | LAM-002A + Rituximab | LAM-002A + Atezolizumab | Total |
|---|---|---|---|---|---|---|---|---|---|
| Age Category — <65 years | 2 | 3 | 1 | 0 | 0 | 9 | 7 | 2 | 24 |
| Age Category — ≥65 years | 1 | 5 | 4 | 4 | 3 | 11 | 5 | 5 | 38 |
| Sex: Female, Male(Participants) | LAM-002A Continuous Monotherapy - 50 mg BID | LAM-002A Continuous Monotherapy - 100 mg BID | LAM-002A Continuous Monotherapy - 150 mg BID | LAM-002A Continuous Monotherapy - 75 mg TID | LAM-002A Intermittent Monotherapy - 150 mg BID | LAM-002A Continuous Monotherapy - 125 mg | LAM-002A + Rituximab | LAM-002A + Atezolizumab | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 5 | 4 | 2 | 2 | 9 | 4 | 3 | 30 |
| Male | 2 | 3 | 1 | 2 | 1 | 11 | 8 | 4 | 32 |
| Race/Ethnicity, Customized(Participants) | LAM-002A Continuous Monotherapy - 50 mg BID | LAM-002A Continuous Monotherapy - 100 mg BID | LAM-002A Continuous Monotherapy - 150 mg BID | LAM-002A Continuous Monotherapy - 75 mg TID | LAM-002A Intermittent Monotherapy - 150 mg BID | LAM-002A Continuous Monotherapy - 125 mg | LAM-002A + Rituximab | LAM-002A + Atezolizumab | Total |
|---|---|---|---|---|---|---|---|---|---|
| Race — White | 3 | 6 | 4 | 3 | 3 | 16 | 11 | 7 | 53 |
| Race — Black/African American | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 4 |
| Race — Other | 0 | 1 | 1 | 0 | 0 | 3 | 0 | 0 | 5 |
| Race/Ethnicity, Customized(Participants) | LAM-002A Continuous Monotherapy - 50 mg BID | LAM-002A Continuous Monotherapy - 100 mg BID | LAM-002A Continuous Monotherapy - 150 mg BID | LAM-002A Continuous Monotherapy - 75 mg TID | LAM-002A Intermittent Monotherapy - 150 mg BID | LAM-002A Continuous Monotherapy - 125 mg | LAM-002A + Rituximab | LAM-002A + Atezolizumab | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ethnicity — Not Hispanic/Latino | 3 | 8 | 5 | 3 | 3 | 16 | 12 | 7 | 57 |
| Ethnicity — Hispanic/Latino | 0 | 0 | 0 | 1 | 0 | 4 | 0 | 0 | 5 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | LAM-002A Continuous Monotherapy - 50 mg BID | LAM-002A Continuous Monotherapy - 100 mg BID | LAM-002A Continuous Monotherapy - 150 mg BID | LAM-002A Continuous Monotherapy - 75 mg TID | LAM-002A Intermittent Monotherapy - 150 mg BID | LAM-002A Continuous Monotherapy - 125 mg | LAM-002A + Rituximab | LAM-002A + Atezolizumab | Total |
|---|---|---|---|---|---|---|---|---|---|
| 0, fully active, able to carry on all predisease performance without restrictions | 0 | 5 | 1 | 1 | 1 | 7 | 3 | 0 | 18 |
| 1, restricted in physically strenuous activity but ambulatory and able to do light or sedentary work | 3 | 3 | 3 | 2 | 2 | 11 | 9 | 6 | 39 |
| 2, ambulatory and capable of all self-care but unable to work. Up more than 50% of waking hours | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 0 | 4 |
| 3, capable of only limited self-care, confined to bed or chair more than 50% of waking hours | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Oct 2015, a primary completion of Mar 2020 and a completion of Mar 2023. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2024, 4 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Apilimod Dimesylate Capsule · Rituximab
OrphAI Therapeutics